{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"TrueLife","title":"Psychedelics in the Treatment of Bipolar & Mental Illness ","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/01d47a05\"></iframe>","width":"100%","height":180,"duration":1963,"description":"https://journalbipolardisorders.springeropen.com/articles/10.1186/s40345-022-00265-5Abstract:This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research. The so-called classic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline and ayahuasca. Characteristic effects like alterations in sensory perception, as well as emotion- and self-processing are induced by stimulation of serotonin 2A receptors in cortical areas. The new paradigm of psychedelic-assisted psychotherapy suggests a therapeutic framework in which a safely conducted psychedelic experience is integrated into a continuous psychotherapeutic process. First randomized, controlled trials with psilocybin show promising efficacy, tolerability, and adherence in the treatment of unipolar depression.","thumbnail_url":"https://img.transistorcdn.com/FV-M9IcfmmK0PpSjnssPkhI7AX9NSl6NdRLN8MmGBl8/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzExODc0LzE2NzI1/NDI0ODQtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}